vs
Side-by-side financial comparison of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) and TELUS CORP (TU). Click either name above to swap in a different company.
TEVA PHARMACEUTICAL INDUSTRIES LTD is the larger business by last-quarter revenue ($4.7B vs $3.7B, roughly 1.3× TELUS CORP). TEVA PHARMACEUTICAL INDUSTRIES LTD runs the higher net margin — 10.2% vs -4.8%, a 15.0% gap on every dollar of revenue. On growth, TEVA PHARMACEUTICAL INDUSTRIES LTD posted the faster year-over-year revenue change (11.4% vs 2.2%).
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
TELUS CORPTUEarnings & Financial Report
Telus Corporation is a Canadian publicly traded holding company and conglomerate, headquartered in Vancouver, British Columbia, which is the parent company of several subsidiaries: Telus Communications offers telephony, television, data and Internet services; Telus Mobility offers wireless services; Telus Health operates companies that provide health products and services; and Telus Digital operates worldwide, providing multilingual customer service outsourcing and digital IT services. Telus ...
TEVA vs TU — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.7B | $3.7B |
| Net Profit | $481.0M | $-178.8M |
| Gross Margin | 56.4% | 90.2% |
| Operating Margin | 6.4% | 3.4% |
| Net Margin | 10.2% | -4.8% |
| Revenue YoY | 11.4% | 2.2% |
| Net Profit YoY | 321.7% | -210.9% |
| EPS (diluted) | $0.42 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.7B | — | ||
| Q3 25 | $4.5B | — | ||
| Q2 25 | $4.2B | $3.7B | ||
| Q1 25 | $3.9B | — | ||
| Q4 24 | $4.2B | — | ||
| Q3 24 | $4.3B | — | ||
| Q2 24 | $4.2B | $3.6B | ||
| Q1 24 | $3.8B | — |
| Q4 25 | $481.0M | — | ||
| Q3 25 | $433.0M | — | ||
| Q2 25 | $282.0M | $-178.8M | ||
| Q1 25 | $214.0M | — | ||
| Q4 24 | $-217.0M | — | ||
| Q3 24 | $-437.0M | — | ||
| Q2 24 | $-846.0M | $161.3M | ||
| Q1 24 | $-139.0M | — |
| Q4 25 | 56.4% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 50.3% | 90.2% | ||
| Q1 25 | 48.2% | — | ||
| Q4 24 | 50.2% | — | ||
| Q3 24 | 49.6% | — | ||
| Q2 24 | 48.6% | 87.9% | ||
| Q1 24 | 46.4% | — |
| Q4 25 | 6.4% | — | ||
| Q3 25 | 19.7% | — | ||
| Q2 25 | 10.9% | 3.4% | ||
| Q1 25 | 13.3% | — | ||
| Q4 24 | -0.7% | — | ||
| Q3 24 | -1.2% | — | ||
| Q2 24 | -0.1% | 13.7% | ||
| Q1 24 | -5.7% | — |
| Q4 25 | 10.2% | — | ||
| Q3 25 | 9.7% | — | ||
| Q2 25 | 6.8% | -4.8% | ||
| Q1 25 | 5.5% | — | ||
| Q4 24 | -5.1% | — | ||
| Q3 24 | -10.1% | — | ||
| Q2 24 | -20.3% | 4.4% | ||
| Q1 24 | -3.6% | — |
| Q4 25 | $0.42 | — | ||
| Q3 25 | $0.37 | — | ||
| Q2 25 | $0.24 | — | ||
| Q1 25 | $0.18 | — | ||
| Q4 24 | $-0.19 | — | ||
| Q3 24 | $-0.39 | — | ||
| Q2 24 | $-0.75 | — | ||
| Q1 24 | $-0.12 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.6B | $2.7B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $7.9B | $11.8B |
| Total Assets | $40.7B | $44.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.6B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.2B | $2.7B | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $3.3B | — | ||
| Q2 24 | $2.3B | $676.7M | ||
| Q1 24 | $3.0B | — |
| Q4 25 | $7.9B | — | ||
| Q3 25 | $7.3B | — | ||
| Q2 25 | $6.8B | $11.8B | ||
| Q1 25 | $6.3B | — | ||
| Q4 24 | $5.4B | — | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $6.4B | $12.4B | ||
| Q1 24 | $7.3B | — |
| Q4 25 | $40.7B | — | ||
| Q3 25 | $39.9B | — | ||
| Q2 25 | $40.1B | $44.3B | ||
| Q1 25 | $38.4B | — | ||
| Q4 24 | $39.3B | — | ||
| Q3 24 | $41.8B | — | ||
| Q2 24 | $41.3B | $41.8B | ||
| Q1 24 | $42.8B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.2B | $851.2M |
| Free Cash FlowOCF − Capex | $1.0B | — |
| FCF MarginFCF / Revenue | 21.6% | — |
| Capex IntensityCapex / Revenue | 3.0% | — |
| Cash ConversionOCF / Net Profit | 2.41× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.1B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.2B | — | ||
| Q3 25 | $369.0M | — | ||
| Q2 25 | $227.0M | $851.2M | ||
| Q1 25 | $-105.0M | — | ||
| Q4 24 | $575.0M | — | ||
| Q3 24 | $693.0M | — | ||
| Q2 24 | $103.0M | $1.0B | ||
| Q1 24 | $-124.0M | — |
| Q4 25 | $1.0B | — | ||
| Q3 25 | $233.0M | — | ||
| Q2 25 | $131.0M | — | ||
| Q1 25 | $-232.0M | — | ||
| Q4 24 | $446.0M | — | ||
| Q3 24 | $545.0M | — | ||
| Q2 24 | $6.0M | — | ||
| Q1 24 | $-248.0M | — |
| Q4 25 | 21.6% | — | ||
| Q3 25 | 5.2% | — | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | -6.0% | — | ||
| Q4 24 | 10.5% | — | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | -6.5% | — |
| Q4 25 | 3.0% | — | ||
| Q3 25 | 3.0% | — | ||
| Q2 25 | 2.3% | — | ||
| Q1 25 | 3.3% | — | ||
| Q4 24 | 3.1% | — | ||
| Q3 24 | 3.4% | — | ||
| Q2 24 | 2.3% | — | ||
| Q1 24 | 3.2% | — |
| Q4 25 | 2.41× | — | ||
| Q3 25 | 0.85× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 6.28× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TEVA
| Other | $2.0B | 42% |
| Generics Medicians Including Otc And Biosimilars | $672.0M | 14% |
| Other Products | $608.0M | 13% |
| License | $529.0M | 11% |
| Distribution Service | $366.0M | 8% |
| Other Activities | $227.0M | 5% |
| Ajovy | $106.0M | 2% |
| COPAXONE | $77.0M | 2% |
| Respiratory Product | $65.0M | 1% |
| Uzedy | $55.0M | 1% |
| Bendeka And Treanda | $36.0M | 1% |
TU
Segment breakdown not available.
